{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:16:05Z","timestamp":1761920165559},"reference-count":45,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Despite the high prevalence of liver disease globally, there are currently no approved anti-fibrotic therapies to treat patients with liver fibrosis. A major goal in anti-fibrotic therapy is the development of drug delivery systems that allow direct targeting of the major pro-scarring cell populations within the liver (hepatic myofibroblasts) whilst not perturbing the homeostatic functions of other mesenchymal cell types present within both the liver and other organ systems. In this review we will outline some of the recent advances in our understanding of myofibroblast biology, discussing both the origin of myofibroblasts and possible myofibroblast fates during hepatic fibrosis progression and resolution. We will then discuss the various strategies currently being employed to increase the precision with which we deliver potential anti-fibrotic therapies to patients with liver fibrosis.<\/ns4:p>","DOI":"10.12688\/f1000research.8822.1","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T12:08:20Z","timestamp":1468930100000},"page":"1749","update-policy":"http:\/\/dx.doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis"],"prefix":"10.12688","volume":"5","author":[{"given":"Ross","family":"Dobie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil C.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"593-608","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data.","volume":"58","author":"M Blachier","year":"2013","journal-title":"J Hepatol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1807-16","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins.","volume":"170","author":"B Hinz","year":"2007","journal-title":"Am J Pathol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"65-8","DOI":"10.1111\/j.1440-1746.2011.07002.x","article-title":"What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.","volume":"27","author":"K Iwaisako","year":"2012","journal-title":"J Gastroenterol Hepatol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1171-80","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis.","volume":"56","author":"E Ellis","year":"2012","journal-title":"J Hepatol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"119-31","DOI":"10.1055\/s-0035-1550057","article-title":"Resolution of liver fibrosis: basic mechanisms and clinical relevance.","volume":"35","author":"P Ramachandran","year":"2015","journal-title":"Semin Liver Dis."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1340-55","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.","volume":"180","author":"B Hinz","year":"2012","journal-title":"Am J Pathol."},{"key":"ref-7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.","volume":"4","author":"I Mederacke","year":"2013","journal-title":"Nat Commun."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"E3297-305","DOI":"10.1073\/pnas.1400062111","article-title":"Origin of myofibroblasts in the fibrotic liver in mice.","volume":"111","author":"K Iwaisako","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"2324-9","DOI":"10.1073\/pnas.1214136110","article-title":"Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury.","volume":"110","author":"Y Li","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"429-38","DOI":"10.1016\/j.jhep.2006.04.014","article-title":"Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis.","volume":"45","author":"T Kisseleva","year":"2006","journal-title":"J Hepatol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"d496-503","DOI":"10.2741\/kinnman","article-title":"Peribiliary myofibroblasts in biliary type liver fibrosis.","volume":"7","author":"N Kinnman","year":"2002","journal-title":"Front Biosci."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"41-7","DOI":"10.1053\/j.gastro.2014.05.001","article-title":"The portal fibroblast: not just a poor man's stellate cell.","volume":"147","author":"R Wells","year":"2014","journal-title":"Gastroenterology."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1617-24","DOI":"10.1038\/nm.3282","article-title":"Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs.","volume":"19","author":"N Henderson","year":"2013","journal-title":"Nat Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1324-32","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis.","volume":"13","author":"E Seki","year":"2007","journal-title":"Nat Med."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"9448-53","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.","volume":"109","author":"T Kisseleva","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1073-83.e22","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice.","volume":"143","author":"J Troeger","year":"2012","journal-title":"Gastroenterology."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"538-49","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.","volume":"102","author":"J Iredale","year":"1998","journal-title":"J Clin Invest."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"657-67","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis.","volume":"134","author":"V Krizhanovsky","year":"2008","journal-title":"Cell."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"8897-902","DOI":"10.1073\/pnas.151136298","article-title":"NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.","volume":"98","author":"S Fiorucci","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"126-39","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.","volume":"203","author":"A D'Souza","year":"2015","journal-title":"J Control Release."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1285-97","DOI":"10.1002\/hep.27936","article-title":"Specific hepatic delivery of procollagen \u03b11(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis.","volume":"62","author":"C Jim\u00e9nez Calvente","year":"2015","journal-title":"Hepatology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"51-66","DOI":"10.1016\/j.stem.2014.11.004","article-title":"Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis.","volume":"16","author":"R Kramann","year":"2015","journal-title":"Cell Stem Cell."},{"key":"ref-23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309655","article-title":"A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.","author":"D Zhang","year":"2015","journal-title":"Gut."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1486-93","DOI":"10.1002\/hep.510290526","article-title":"Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells.","volume":"29","author":"L Beljaars","year":"1999","journal-title":"Hepatology."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"320-8","DOI":"10.1034\/j.1600-0676.2001.210504.x","article-title":"Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA).","volume":"21","author":"L Beljaars","year":"2001","journal-title":"Liver."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1220-7","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.","volume":"57","author":"S Klein","year":"2012","journal-title":"J Hepatol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"942-52","DOI":"10.1002\/hep.23419","article-title":"Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats.","volume":"51","author":"M Moreno","year":"2010","journal-title":"Hepatology."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"560-7","DOI":"10.1016\/j.jhep.2005.08.027","article-title":"Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems.","volume":"44","author":"J Adrian","year":"2006","journal-title":"J Hepatol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"628-35","DOI":"10.1124\/jpet.111.179143","article-title":"Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.","volume":"337","author":"M van Beuge","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1237-42","DOI":"10.1016\/j.drudis.2013.05.013","article-title":"Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver.","volume":"18","author":"K Poelstra","year":"2013","journal-title":"Drug Discov Today."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"326-30","DOI":"10.1016\/j.jconrel.2011.06.037","article-title":"Targeted TFO delivery to hepatic stellate cells.","volume":"155","author":"N Yang","year":"2011","journal-title":"J Control Release."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"814-21","DOI":"10.1124\/dmd.106.013490","article-title":"Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine.","volume":"35","author":"H Rachmawati","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"12743-51","DOI":"10.1074\/jbc.275.17.12743","article-title":"Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor.","volume":"275","author":"L Beljaars","year":"2000","journal-title":"J Biol Chem."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"560-8","DOI":"10.1124\/jpet.107.122481","article-title":"Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats.","volume":"322","author":"S Du","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1307-17","DOI":"10.1016\/S0006-2952(03)00445-3","article-title":"The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue.","volume":"66","author":"L Beljaars","year":"2003","journal-title":"Biochem Pharmacol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"18-24","DOI":"10.1016\/j.jconrel.2014.01.022","article-title":"Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo.","volume":"179","author":"R Bansal","year":"2014","journal-title":"J Control Release."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"586-96","DOI":"10.1002\/hep.24395","article-title":"Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice.","volume":"54","author":"R Bansal","year":"2011","journal-title":"Hepatology."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"431-42","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.","volume":"26","author":"Y Sato","year":"2008","journal-title":"Nat Biotechnol."},{"key":"ref-39","first-page":"G947-52","article-title":"Retinol release by activated rat hepatic lipocytes: regulation by Kupffer cell-conditioned medium and PDGF.","volume":"264","author":"S Friedman","year":"1993","journal-title":"Am J Physiol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"888-96","DOI":"10.1016\/j.jhep.2005.01.028","article-title":"Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells--a potential mechanism for targeting liver anti-fibrotic therapeutics.","volume":"42","author":"L Elrick","year":"2005","journal-title":"J Hepatol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"88-98","DOI":"10.1016\/j.jhep.2008.01.032","article-title":"Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.","volume":"49","author":"A Douglass","year":"2008","journal-title":"J Hepatol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"399-406","DOI":"10.1021\/mp700118p","article-title":"PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells.","volume":"5","author":"M Schoemaker","year":"2008","journal-title":"Mol Pharm."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"797-808","DOI":"10.1016\/j.stem.2016.01.010","article-title":"Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis.","volume":"18","author":"G Song","year":"2016","journal-title":"Cell Stem Cell."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"e67091","DOI":"10.1371\/journal.pone.0067091","article-title":"Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo.","volume":"8","author":"J Reetz","year":"2013","journal-title":"PLoS One."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"809-16","DOI":"10.1016\/j.stem.2016.05.005","article-title":"In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis.","volume":"18","author":"M Rezvani","year":"2016","journal-title":"Cell Stem Cell."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:36:14Z","timestamp":1553254574000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":45,"URL":"https:\/\/doi.org\/10.12688\/f1000research.8822.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.9497.r15092","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9497.r15093","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9497.r15094","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.9497.r15092, Tatiana Kisseleva, Department of Surgery, University of California San Diego, La Jolla, CA, USA, 19 Jul 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1#referee-response-15092","order":0,"name":"referee-response-15092","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9497.r15093, Frank Tacke, Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany, 19 Jul 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1#referee-response-15093","order":1,"name":"referee-response-15093","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9497.r15094, Scott L Friedman, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 19 Jul 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1749\/v1#referee-response-15094","order":2,"name":"referee-response-15094","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The authors acknowledge the support of CORE\/Children\u2019s Liver Disease Foundation and the Wellcome Trust.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}